Return to search

Locanabio pulls in $100m Series B

Locanabio Inc, an RNA-targeting gene therapy company, has raised $100 million in Series B financing.

Locanabio Inc, an RNA-targeting gene therapy company, has raised $100 million in Series B financing. Vida Ventures led the round with participation from other investors that included RA Capital Management, Invus, Acuta Capital Partners, SVB Leerink, ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures and GV.

Source: Press Release